linjc16/ctgov huggingface dataset:
Early Detection of Barrett's Esophagus Through Deep Image Retrieval

Study Overview
=================
Brief Summary
-----------------
Barrett's oesophagus is a condition in which the area between the oesophagus and stomach no longer closes, allowing acidic contents of the stomach to enter the oesophagus and damage the lining. The project aims to assist clinicians by offering informed biopsy process, in which the system presents the operator with clinical outcomes of patients with visually similar GI tracts. The project goal is to assess the use of artificial intelligence-based similarity detection systems to better inform biopsy placement, increasing the reliability of bi-yearly inspections.

Detailed Description
-----------------
The project intention is to acquire secondary endoscopy captured data from clinicians to create a sufficient dataset to train a learning system to achieve the stated objective. The data required will feature footage (images/videos) from inside the oesophagus. The preferred data would contain associated diagnosis notes and description, however, data without diagnosis can still be used. All data can and will be anonymised, as personal information will not be useful in this work. The data will be labelled by either researchers, or professional clinicians and prepared ready to feed into a chosen learning AI system. Through an iterative learning process, the chosen AI system will learn to discriminate between severity of Barrett's oesophagus and output optimal biopsy target.

Official Title
-----------------
Early Detection of Cancer in Cases of Barrett's Esophagus Using Robotic Endoscopy Image Analysis Through Deep Image Retrieval

Conditions
-----------------
Barrett Esophagus

Intervention / Treatment
-----------------
* Diagnostic Test: Gastroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Attending Southmead Hospital for on OGD Has capacity Initially any indication, later patients with known Barrett's oesophagus Exclusion Criteria: Children (<18) Patients without capacity Urgent and emergency procedures Limited English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gastroscopy clinic patients<br>NBT gastroscopy clinic invited participants. Patients are already due to attend the clinic, and we are inviting them to share their gastroscopy data with our research study. | Diagnostic Test: Gastroscopy<br>* Routine gastroscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gastroscopy image data set | Images collected during routine gastroscopy with examination notes | 12 months |
DMT310-005 Topical in the Treatment of Acne Rosacea

Study Overview
=================
Brief Summary
-----------------
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne rosacea.

Official Title
-----------------
A Study Of The Tolerability, Safety, And Efficacy Of DMT310 For The Treatment Of Acne Rosacea

Conditions
-----------------
Acne Rosacea

Intervention / Treatment
-----------------
* Drug: Topical Powder
* Drug: Placebo Topical Powder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is male or non-pregnant female at least 18 years of age. Clinical diagnosis of moderate to severe papulopustular acne rosacea as determined by: Investigator's Global Assessment (IGA) at Randomization score of 3 or 4. Patient has at least 15 inflammatory lesions on the face Patient is willing to apply the Investigational Product as directed Patient is willing and able to comply with the protocol Exclusion Criteria: Patient is pregnant or planning to become pregnant Patient is taking a topical therapy on the face which may affect the patient's rosacea

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study Treatment 1<br>DMT310 Powder mixed with Hydrogen Peroxide | Drug: Topical Powder<br>* Topical Powder mixed with diluent<br>|
| Experimental: Study Treatment 2<br>Placebo powder mixed with Hydrogen Peroxide | Drug: Placebo Topical Powder<br>* Placebo Topical Powder mixed with diluent<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy as measured by lesion counts | Inflammatory lesion counts | 12 Weeks | 
| Efficacy as measured by Investigator Global Assessment (IGA) | IGA Scale: 0 Clear No papules and/or pustules Almost Clear Rare papules and/or pustules Mild Few papules and/or pustules Moderate Pronounced number of papules and/or pustules (but less than numerous papules and/or pustules) Severe Numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions | 12 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events as a measure of safety and tolerability | Incidence of adverse events as a measure of safety and tolerability | 12 Weeks |
Hyperbaric Oxygen Treatment in Patients With White Matter Hyperintensities

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to assess whether hyperbaric oxygen treatment improves neurological function in patients who exhibit white matter hyperintensities on MRI examination. The secondary goal of this study is to determine if it is possible using MRI to discern a difference in perfusion of central nervous system tissue in regions of white matter hyperintensities after hyperbaric oxygen administration as compared to hyperbaric air.

Detailed Description
-----------------
Consecutively enrolled patients will be assigned to hyperbaric oxygen or hyperbaric air by random number. Physicians supervising the hyperbaric treatments and the treating technicians, the evaluating neurologist, and the interpreter of the MRIs will be blinded regarding patient treatment status. All patients who receive placebo will be offered treatment with hyperbaric oxygen.

Official Title
-----------------
Hyperbaric Oxygen Treatment In Patients With White Matter Hyperintensities On Magnetic Resonance Imaging and Neurologic Deficits

Conditions
-----------------
Neurological Impairments, Leukoencephalopathies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 50 years of age White Matter Hyperintensities on MRI of brain Two or more symptoms and/or Neurological impairments e.g. gait disturbance, dysequilibrium, decline in cognitive function, upper motor neuron deficit, dysmetria, hyper-reflex or unilateral increase in muscle tone Exclusion Criteria: Contraindications to hyperbaric oxygen therapy e.g. pulmonary emphysema or bullae, claustrophobia, seizure disorder Inability of the patient to tolerate pressurization e.g. eustachian tube dysfunction Extreme cognitive impairment Major Depression Other uncontrolled co-morbidities e.g. diabetes, hypertension, thyroid disorders, carotid artery stenosis (over 70%), renal or hepatic dysfunction History of brain tumor, head trauma, electroshock therapy,brain irradiation or migraine headaches

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rating scores on the physical/neurological examinations are qualitative, comparisons between the treated and the placebo groups must be analyzed utilizing non-parametric tests. |  | After thirty patients have completed treatment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A qualitative evaluation will be scored as positive or negative. Twenty patients will allow this determination. |  | After twenty patients have recieved treatment. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyperbaric Oxygen
Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus

Study Overview
=================
Brief Summary
-----------------
This study is designed pre-operative for patients with resectable, local-regional carcinoma of the esophagus.

Detailed Description
-----------------
This study is designed for patients with resectable, local-regional carcinoma of the esophagus. In a pre-operative setting, chemotherapy with Taxol, Cisplatin, and 5-Fluorouracil will be administered followed by G-CSF.

Official Title
-----------------
Phase II Study of Pre-Operative Chemotherapy With Taxol, Cisplatin, and 5-Fluorouracil Followed by G-CSF in Patients With Resectable Local-Regional Carcinoma of Esophagus

Conditions
-----------------
Esophageal Diseases

Intervention / Treatment
-----------------
* Drug: Taxol, Cisplatin, 5-Fluorouracil, G-CSF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Measurable disease with resectable local-regional carcinoma of the esophagus. 18 years of age or older. Exclusion Criteria: Pregnant or lactating. Non-resectable local-regional carcinoma of the esophagus.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Taxol, Cisplatin, 5-Fluorouracil, G-CSF|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Esophageal Diseases
Evaluation of Capillary Refill Index

Study Overview
=================
Brief Summary
-----------------
Comparison of a peripheral perfusion assessment method using a pulse oximeter to the conventional capillary refill time visually assessed by a clinician.

Detailed Description
-----------------
A new technology, capillary refill index (CRI), to assess peripheral perfusion status quantitatively using pulse oximeter waveforms is being developed. The conventional capillary refill time (CRT) is widely used in clinical settings as a gold standard to assess peripheral perfusion. The objective of this study is to evaluate the capability of CRI to predict altered peripheral perfusion determined with the conventional CRT test. Predictive capability of CRI needs to be assessed to achieve a goal to provide clinicians with an alternative method to the conventional CRT.

Official Title
-----------------
Evaluation of Capillary Refill Index

Conditions
-----------------
Perfusion; Complications

Intervention / Treatment
-----------------
* Device: capillary refill index (CRI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals 18 years of age or older Patients who present to the ED or who are admitted to the ICU of North Shore University Hospital (NSUH) Exclusion Criteria: Pregnant Prisoners Finger, hand or forearm anatomical anomaly or disease that may interfere with attaching a pulse oximeter sensor Patients' deemed clinically unstable by the clinical team

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictive Capability of the Altered Peripheral Perfusion | The area under the curve (AUC) of the receiver operator characteristic (ROC) curve analysis on CRI values to predict probability of altered peripheral perfusion determined with the CRT test. | < 30 min *right after enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Device CRI to Conventional (Visual) CRT | Spearman's correlation coefficient to assess the correlation between CRI and CRT values. | < 30 min *right after enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
capillary refill time, peripheral perfusion
Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, Prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of albumin-bound paclitaxel in patients with recurrent or metastatic breast cancer and its impact on quality of life.

Official Title
-----------------
Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: Observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In patients with breast cancer who have been treated with albumin-bound paclitaxel for the treatment of metastatic breast cancer who failed to undergo chemotherapy or who have relapsed within 6 months after adjuvant chemotherapy, unless there is a clinical contraindication, the previous chemotherapy regimen must include an a anthracycline drug Exclusion Criteria: No
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observational study|Observational study of this study, no interventions involved|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage and severity of Participants With Adverse Events (AEs) | percentage and CTC AE(v4.0) of AEs | 28 days after the end of the last chemotherapy cycle | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate (ORR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | ORR is defined as the rate of CR or PR, as determined by IRC using RECIST v1.1 criteria. | From signing informed consent，assessed up to end of study (up to approximately 24months) | 
| evaluate patients' quality of life by the European Cancer Research and Treatment Tissue Cancer Quality Core Questionnaire EORTCQLQ-C30 | EORTC QLQC30 scale was used to score the quality of life before treatment, at each chemotherapy cycle, and at the end of treatment. | From signing informed consent，assessed up to end of study (up to approximately 24months) |
pRedicting the Long-term rEsponse of High Frequency sPinal cOrd sTimulation in Patients With Failed Back Surgery Syndrome.

Study Overview
=================
Brief Summary
-----------------
The aim of the current retrospective study is to predict responders for HF10-SCS therapy by only using baseline data. Data collected through clinical practice until June 2020 will be used in this retrospective analysis.

Official Title
-----------------
pRedicting the Long-term rEsponse of High Frequency sPinal cOrd sTimulation in Patients With Failed Back Surgery Syndrome.

Conditions
-----------------
Failed Back Surgery Syndrome

Intervention / Treatment
-----------------
* Other: pain intensity reporting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: FBSS patients treated with high frequency spinal cord stimulation implantation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FBSS patients<br>FBSS patients who are treated with high frequency Spinal Cord Stimulation | Other: pain intensity reporting<br>* pain intensity reporting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Responder status | A responder is defined as a patient who has 50% pain relief for the predominant pain location at the last follow-up visit compared to baseline. | The difference in pain intensity from the date that a patient was eligible for Spinal Cord Stimulation (i.e. baseline) up to the date of the last routine care visit with Spinal Cord Stimulation with database lock at 15th of June 2020. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prediction, High frequency Spinal Cord Stimulation
Ball and Socket Versus Locator Attachment Retained Implant Overdentures

Study Overview
=================
Brief Summary
-----------------
Will the use of locator attachment influence the muscle efficacy when compared to ball and socket attachment in mandibular implant overdenture? '

Detailed Description
-----------------
In this study we will use a two different types of attachments in implants overdenture in mandibular completely edentulous patients to increase the retention and stability of the denture and this can be recognized by record the masticatory function of the muscles of the mandibular jaw.

Official Title
-----------------
Comparison of Muscle Activity and Patients Satisfaction on Implants Supported Overdenture Using Ball and Socket Versus Locator Attachment

Conditions
-----------------
Complete Edentulism

Intervention / Treatment
-----------------
* Device: Locator Attachment (positioner)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Upper and lower completely edentulous patients. Acceptance of the existing denture if it is good, or constructing a new one if it is defected. Patients with adequate bone quality and quantity. Tooth extracted not less than 6 month. Exclusion Criteria: Young patients. Diseases affecting neuromuscular coordination. TMJ diseases. Soft tissue abnormalities. Bony exostosis. Parathyroid dysfunction uncontrolled Diabetes Radiotherapy to the neck or head Pregnancy. Drug and alcohol dependency. Smokers.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ball and socket<br>It is an attachment retaining implant overdentures to increase retention and stability of the denture | Device: Locator Attachment (positioner)<br>* intra oral attachment<br>|
| Experimental: Locator attachment<br>attachment retaining implant overdentures | Device: Locator Attachment (positioner)<br>* intra oral attachment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle Activity | Digital Electromyogram | 6 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Satisfaction: questionnaire | questionnaire from zero to 10 where zero is completely unsatisfied and 10 is highly satisfied | 6 month |
Hypertonic Saline Dextran in Pediatric Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether infusion of hypertonic saline dextran attenuates the inflammatory response and the water overload, during and after major cardiac surgery in small children.

Detailed Description
-----------------
After major cardiac surgery in small children, extravasation of fluid due to increased capillary leak has negative effect on haemodynamics and respiration. Inflammation cascades are activated by surgery and the use of cardio pulmonary bypass (CPB). We want to test whether a small infusion of 7.5% NaCl in 6% dextran solution before and after CPB reduces inflammatory activation by measuring the levels of interleukins 6 and 8 (IL-6, IL-8). We also measure extravascular lung water, fluid balance and weight during the first 24 hours post CPB.

Official Title
-----------------
The Use of Hypertonic Saline Dextran in Cardiac Surgery Utilizing Cardio Pulmonary Bypass in Children Less Than 17 Weeks Old.

Conditions
-----------------
Heart Defects, Congenital, Transposition of Great Vessels, Heart Septal Defects, Ventricular, Endocardial Cushion Defects

Intervention / Treatment
-----------------
* Drug: 7.5% NaCl in 6% dextran 70 solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with congenital heart defect undergoing surgery using cardio pulmonary bypass (CPB). Age below 17 weeks Exclusion Criteria: Preoperative: organ failure (other than heart), serum sodium > 155 mmol/l, central venous pressure > 12 mmHg Perioperative: core temperature < 25 ºC on CPB, re-heparinization, re-operation

Ages Eligible for Study
-----------------
Maximum Age: 16 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: 7.5% NaCl in 6% dextran 70 solution|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IL-6 and IL-8 2 hours post CPB |  |  | 
| Extra vascular lung water 2 and 24 hours post CPB |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fluid balance |  |  | 
| Weight gain |  |  | 
| Cardiac output |  |  | 
| Intrathorasic blood volume |  |  | 
| Blood pressure during the first 24 hours post CPB |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infant, Cardiac Surgery, Infant, Newborn, Hypertonic Solutions, Saline Solution, Hypertonic, Capillary leak, Inflammation Mediators